Skip to main content
. 2017 Jan 17;2017(1):CD004143. doi: 10.1002/14651858.CD004143.pub5

Comparison 2. Women with cardiovascular disease (selected outcomes: death, CVD, cognition, QOL).

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Death from any cause: oestrogen‐only HT 3   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
1.1 CEE 0.625 mg (mod dose) daily for 3 years (2.8‐3.2) 2 327 Risk Ratio (M‐H, Fixed, 95% CI) 1.31 [0.53, 3.22]
1.2 Oestradiol valerate 2 mg (mod dose) for 2 years 1 1017 Risk Ratio (M‐H, Fixed, 95% CI) 0.81 [0.51, 1.27]
2 Death from any cause: oestrogen‐only or combined sequential HT 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
2.1 Oestradiol 1 mg (low dose) daily (if no uterus) plus MPA 5 mg for 12 days a year (if uterus intact) for 2.8 years 1 664 Risk Ratio (M‐H, Fixed, 95% CI) 1.14 [0.77, 1.67]
3 Death from any cause: combined continuous HT 3   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
3.1 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 2.8‐3.2 years 2 297 Risk Ratio (M‐H, Fixed, 95% CI) 0.86 [0.28, 2.62]
3.2 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 4 years 1 2763 Risk Ratio (M‐H, Fixed, 95% CI) 1.06 [0.84, 1.34]
3.3 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 4‐7 years UNBLINDED 1 2321 Risk Ratio (M‐H, Fixed, 95% CI) 1.14 [0.90, 1.44]
4 Death from coronary heart disease: oestrogen‐only HT 3   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
4.1 CEE 0.625 mg (mod dose) daily for 2.8‐3.2 years 2 327 Risk Ratio (M‐H, Fixed, 95% CI) 1.31 [0.36, 4.77]
4.2 Oestradiol valerate 2 mg (mod dose) for 2 years 1 1017 Risk Ratio (M‐H, Fixed, 95% CI) 0.69 [0.40, 1.18]
5 Death from CHD: oestrogen‐only or combined sequential HT 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
5.1 Oestradiol 1 mg (low dose) daily (if no uterus) plus MPA 5 mg for 12 days a year (if uterus intact) for 2.8 years 1 664 Risk Ratio (M‐H, Fixed, 95% CI) 0.82 [0.37, 1.81]
6 Death from CHD: combined continuous HT 3   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
6.1 CEE 0.625 mg (mod dose) daily + MPA 2.5 mg for 1 year 1 2763 Risk Ratio (M‐H, Fixed, 95% CI) 1.55 [0.73, 3.29]
6.2 CEE 0.625 mg (mod dose) daily + MPA 2.5 mg for 2 years 1 2763 Risk Ratio (M‐H, Fixed, 95% CI) 1.50 [0.90, 2.51]
6.3 CEE 0.625 mg (mod dose) daily + MPA 2.5 mg for 3 years (2.8‐3.2) 3 3060 Risk Ratio (M‐H, Fixed, 95% CI) 1.30 [0.88, 1.90]
6.4 CEE 0.625 mg (mod dose) daily + MPA 2.5 mg for 4+ years (median 4.1) 1 2763 Risk Ratio (M‐H, Fixed, 95% CI) 1.19 [0.85, 1.67]
6.5 CEE 0.625 mg (mod dose) daily + MPA 2.5 mg for 4‐6.8 years 1 2321 Risk Ratio (M‐H, Fixed, 95% CI) 0.99 [0.71, 1.39]
7 Coronary event (MI or cardiac death): oestrogen‐only HT 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
7.1 Oestradiol valerate 2 mg (mod dose) for 2 years 1 1017 Risk Ratio (M‐H, Fixed, 95% CI) 1.00 [0.72, 1.39]
8 Death from stroke: oestrogen‐only or combined sequential HT 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
8.1 Oestradiol 1 mg (low dose) daily (if no uterus) plus MPA 5 mg for 12 days a year (if uterus intact) for 2.8 years 1 664 Risk Ratio (M‐H, Fixed, 95% CI) 2.91 [0.95, 8.93]
9 Death from cancer: combined continuous HT 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
9.1 CEE 0.625 mg daily (mod dose) + MPA 2.5 mg for 4+ years (median 4.1) 1 2763 Risk Ratio (M‐H, Fixed, 95% CI) 0.88 [0.49, 1.57]
9.2 CEE 0.625 mg daily (mod dose) + MPA 2.5 mg for 4‐6.8 years UNBLINDED 1 2321 Risk Ratio (M‐H, Fixed, 95% CI) 1.51 [0.86, 2.65]
10 Coronary event (MI or cardiac death): oestrogen‐only HT 2   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
10.1 CEE 0.625 (mod dose) daily for 2.8‐3.2 years 2 327 Risk Ratio (M‐H, Fixed, 95% CI) 1.13 [0.54, 2.40]
11 Coronary event: oestrogen‐only or combined sequential HT 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
11.1 Oestradiol 1 mg (low dose) daily (if no uterus) plus MPA 5 mg for 12 days a year (if uterus intact) for 2.8 years 1 664 Risk Ratio (M‐H, Fixed, 95% CI) 0.97 [0.57, 1.65]
12 Coronary event (MI or cardiac death): combined continuous HT 3   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
12.1 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 1 year 1 2763 Risk Ratio (M‐H, Fixed, 95% CI) 1.50 [1.00, 2.25]
12.2 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 2 years 1 2763 Risk Ratio (M‐H, Fixed, 95% CI) 1.20 [0.91, 1.58]
12.3 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 3 years (2.8‐3.2) 3 3060 Risk Ratio (M‐H, Fixed, 95% CI) 1.07 [0.86, 1.33]
12.4 CEE 0.625 mg (mod dose) + MPA 2.5 mg for median 4.1 years 1 2763 Risk Ratio (M‐H, Fixed, 95% CI) 0.99 [0.81, 1.19]
12.5 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 4‐6.8 years UNBLINDED 1 2321 Risk Ratio (M‐H, Fixed, 95% CI) 1.01 [0.78, 1.29]
13 Stroke (first or recurrent): oestrogen‐only HT or combined sequential 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
13.1 Oestradiol 1 mg daily (low dose) (if no uterus) plus MPA 5 mg for 12 days a year (if uterus intact) for 2.8 years 1 664 Risk Ratio (M‐H, Fixed, 95% CI) 1.09 [0.79, 1.51]
14 Stroke (first or recurrent): oestrogen‐only HT (mod dose) 2   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
14.1 CEE 0.625 mg (mod dose) daily for 2.8 years 1 122 Risk Ratio (M‐H, Fixed, 95% CI) 0.69 [0.12, 3.98]
14.2 Oestradiol valerate 2 mg (mod dose) for 2 years 1 1017 Risk Ratio (M‐H, Fixed, 95% CI) 1.64 [0.60, 4.47]
15 Stroke (first or recurrent): combined continuous HT (mod dose oestrogen) 3   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
15.1 Continuous oestradiol 2 mg (mod dose) + norethisterone acetate 1 mg for 1.3 years 1 140 Risk Ratio (M‐H, Fixed, 95% CI) 0.32 [0.01, 7.82]
15.2 CEE 0.625 mg (mod dose) + MPA for 2.8 years 1 88 Risk Ratio (M‐H, Fixed, 95% CI) 5.23 [0.26, 105.85]
15.3 CEE 0.625 mg (mod dose) + MPA 2.5 mg for median 4.1 years 1 2763 Risk Ratio (M‐H, Fixed, 95% CI) 1.23 [0.90, 1.68]
15.4 CEE 0.625 mg (mod dose) + MPA for 4‐6.8 years UNBLINDED 1 2321 Risk Ratio (M‐H, Fixed, 95% CI) 1.05 [0.71, 1.57]
16 Transient ischaemic attack: oestrogen‐only HT (mod dose) 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
16.1 Oestradiol valerate 2 mg (mod dose) for 2 years 1 1017 Risk Ratio (M‐H, Fixed, 95% CI) 1.13 [0.54, 2.36]
17 Transient ischaemic attack: oestrogen‐only or combined sequential HT 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
17.1 Oestradiol 1 mg (low dose) daily (if no uterus) plus MPA 5 mg for 12 days a year (if uterus intact) for 2.8 years 1 664 Risk Ratio (M‐H, Fixed, 95% CI) 1.16 [0.70, 1.94]
18 Transient ischaemic attack: combined continuous HT 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
18.1 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 4 years 1 2763 Risk Ratio (M‐H, Fixed, 95% CI) 0.80 [0.51, 1.23]
18.2 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 4‐6.8 years UNBLINDED 1 2321 Risk Ratio (M‐H, Fixed, 95% CI) 0.95 [0.49, 1.84]
19 Stroke or transient ischaemic attack: oestrogen‐only HT 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
19.1 CEE 0.625 mg (mod dose) daily for 3.2 years 1 205 Risk Ratio (M‐H, Fixed, 95% CI) 0.88 [0.28, 2.78]
20 Stroke or transient ischaemic attack: combined continuous HT 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
20.1 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 3.2 years 1 209 Risk Ratio (M‐H, Fixed, 95% CI) 1.01 [0.34, 3.03]
21 VTE (first or recurrent PE or DVT): oestrogen‐only HT 3   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
21.1 Oestradiol valerate 2 mg (mod dose) for 2 years 1 1017 Risk Ratio (M‐H, Fixed, 95% CI) 1.23 [0.33, 4.55]
21.2 CEE 0.625 mg (mod dose) daily for 2.8‐3.2 years 2 327 Risk Ratio (M‐H, Fixed, 95% CI) 1.64 [0.44, 6.17]
22 VTE (first or recurrent PE or DVT): combined continuous HT 4   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
22.1 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 1 year 1 2763 Risk Ratio (M‐H, Fixed, 95% CI) 3.26 [1.06, 9.96]
22.2 Continuous oestradiol 2 mg (mod dose) + norethisterone acetate 1 mg for 1.3 years 1 140 Risk Ratio (M‐H, Fixed, 95% CI) 6.80 [0.86, 53.85]
22.3 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 2 years 1 2763 Risk Ratio (M‐H, Fixed, 95% CI) 3.51 [1.42, 8.66]
22.4 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 3 years (2.8‐3.2) 3 3060 Risk Ratio (M‐H, Fixed, 95% CI) 3.01 [1.50, 6.04]
22.5 CEE 0.625 mg (mod dose) + MPA 2.5 mg for median 4.1 years 1 2763 Risk Ratio (M‐H, Fixed, 95% CI) 2.62 [1.39, 4.94]
22.6 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 4‐7 years UNBLINDED 1 2321 Risk Ratio (M‐H, Fixed, 95% CI) 1.37 [0.63, 2.98]